Project Details
Description
A randomized, blinded, phase 2 dose-ranging study of BMS-936558 in subjects with progressive advanced/metastatic clear cell renal carcinoma who have received prior anti-angiogenic therapy
Status | Finished |
---|---|
Effective start/end date | 3/21/11 → 8/31/15 |
Funding
- BRISTOL-MYERS SQUIBB PHARM RES